Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more
Jazz Pharmaceuticals PLC (JAZZ) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.084x
Based on the latest financial reports, Jazz Pharmaceuticals PLC (JAZZ) has a cash flow conversion efficiency ratio of 0.084x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($362.52 Million) by net assets ($4.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jazz Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Jazz Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jazz Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jazz Pharmaceuticals PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metso Oyj
HE:METSO
|
0.054x |
|
J.M. Smucker Co.
LSE:0L7F
|
0.107x |
|
Santos Ltd
PINK:STOSF
|
0.093x |
|
Kuehne + Nagel International AG
PINK:KHNGF
|
0.210x |
|
Service Corporation International
NYSE:SCI
|
0.130x |
|
BASF SE
F:BASA
|
0.047x |
|
Kirin Holdings Co Ltd
PINK:KNBWY
|
0.071x |
|
Tsingtao Brewery Co Ltd
PINK:TSGTY
|
0.032x |
Annual Cash Flow Conversion Efficiency for Jazz Pharmaceuticals PLC (2005–2025)
The table below shows the annual cash flow conversion efficiency of Jazz Pharmaceuticals PLC from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.32 Billion | $1.36 Billion | 0.314x | -7.93% |
| 2024-12-31 | $4.09 Billion | $1.40 Billion | 0.341x | +16.69% |
| 2023-12-31 | $3.74 Billion | $1.09 Billion | 0.292x | -29.11% |
| 2022-12-31 | $3.09 Billion | $1.27 Billion | 0.412x | +109.95% |
| 2021-12-31 | $3.97 Billion | $778.51 Million | 0.196x | -20.13% |
| 2020-12-31 | $3.66 Billion | $899.65 Million | 0.246x | -1.50% |
| 2019-12-31 | $3.11 Billion | $776.40 Million | 0.250x | -13.86% |
| 2018-12-31 | $2.76 Billion | $798.90 Million | 0.290x | +13.41% |
| 2017-12-31 | $2.71 Billion | $693.09 Million | 0.255x | -18.79% |
| 2016-12-31 | $1.88 Billion | $590.54 Million | 0.315x | -5.47% |
| 2015-12-31 | $1.60 Billion | $531.94 Million | 0.333x | +12.45% |
| 2014-12-31 | $1.37 Billion | $405.76 Million | 0.296x | +35.17% |
| 2013-12-31 | $1.30 Billion | $283.62 Million | 0.219x | -1.71% |
| 2012-12-31 | $1.12 Billion | $249.75 Million | 0.223x | -71.67% |
| 2011-12-31 | $192.79 Million | $151.60 Million | 0.786x | -59.19% |
| 2010-12-31 | $30.55 Million | $58.87 Million | 1.927x | +783.83% |
| 2009-12-31 | $-72.83 Million | $-15.88 Million | 0.218x | -84.45% |
| 2008-12-31 | $-92.88 Million | $-130.23 Million | 1.402x | +195.09% |
| 2007-12-31 | $54.99 Million | $-81.09 Million | -1.475x | -553.30% |
| 2006-12-31 | $-176.30 Million | $-57.35 Million | 0.325x | -26.26% |
| 2005-12-31 | $-118.25 Million | $-52.16 Million | 0.441x | -- |